Tabak Travels to Kansas for Announcement of New Cancer Center
Shown at an event celebrating a new cancer center are (from l) Sen. Jerry Moran; Rachel Pepper, chief nursing officer, Kansas City Division, University of Kansas Health System; Dr. Joseph McGuirk, director, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City; Britany Leiker, nurse manager, University of Kansas Medical Center, Kansas City; Tammy Peterman, president, Kansas City Division, University of Kansas Health System; Dr. Roy Jensen, director, University of Kansas Cancer Center, Kansas City; Dr. Doug Girod, chancellor, University of Kansas, Lawrence; Bob Page, president and CEO, University of Kansas Health System, Kansas City; and NIH Acting Director Dr. Lawrence Tabak.
Photo: Elissa Monroe/University of Kansas Medical Center
Tabak (l) chats with Jensen during a tour of University of Kansas health facilities.
Photo: Elissa Monroe/University of Kansas Medical Center
A group assembles to hear about construction of a new building bringing together several sites.
Photo: Elissa Monroe/University of Kansas Medical Center
Acting NIH Director Dr. Lawrence Tabak traveled to Kansas on June 27 and joined U.S. Sen. Jerry Moran (R-KS) to celebrate progress toward construction of a new building for the University of Kansas Cancer Center (KUCC). The $143 million facility will be built using a combination of government and private funding and will bring together KUCC’s seven current unique sites.
“As I witnessed firsthand, the strong community support for the new facility illustrates the power of a vibrant public-private partnership to enhance cancer care within the state,” Tabak posted later. The event was held at the University of Kansas Health Education Building in Kansas City.
While there, Tabak toured the Cambridge Street site of KU’s cancer center, visiting the blood and marrow transplant unit, and the Alzheimer’s Disease Research Center, which is located several miles south of Kansas City in Fairway, Kan.